Elutia Inc (ELUT) Q4 2025 Earnings Call Transcript

Why It Matters

LU Pro’s rapid hospital penetration and margin expansion position Elutia for scalable revenue growth, while litigation resolution and pipeline progress de‑risk the business for investors.

Key Takeaways

• LU Pro revenue grew 49% sequentially
• Hospital adoption reached 161 systems, adding 12‑15 monthly
• Boston Scientific partners on 98 hospitals, 30% of market
• Adjusted gross margin rose to 62.4%, >80% on cardiovascular
• Litigation settled 27 lawsuits, 97 of 110 cases resolved

Pulse Analysis

Elutia’s LU Pro bio‑envelope is gaining traction at an unprecedented pace, now active in 161 hospital systems with 12‑15 new adopters each month. Seven national GPO contracts and a strategic partnership with Boston Scientific—present in 98 hospitals and covering roughly 30% of potential pacemaker sites—have amplified distribution efficiency. This commercial momentum translates into a projected $20 million revenue run‑rate for 2025, positioning LU Pro as a multi‑hundred‑million‑dollar opportunity in the U.S. cardiac device market.

Financially, the quarter showed flat total revenue at $6.3 million but highlighted a dramatic margin shift, with adjusted gross margin climbing to 62.4% and cardiovascular products delivering over 80% margins. While adjusted EBITDA recorded a $3.8 million loss, the company attributes this to reinvestment in sales infrastructure and product development. A robust cash balance of $8.5 million, bolstered by anticipated business‑development transactions, provides runway for continued expansion. Crucially, the settlement of 27 lawsuits and resolution of 97 legacy cases removes a lingering liability, improving the balance sheet and investor confidence.

Looking ahead, Elutia’s pipeline centers on the NXT 41 matrix for breast reconstruction, a market estimated at $1.5 billion in the U.S. with biologics accounting for 65% of implant‑related spend. The base matrix is slated for FDA submission in 2026, followed by an antibiotic‑enhanced version in 2027, addressing high infection rates that drive costly complications. Successful entry into this space could diversify revenue streams and cement Elutia’s position as a leader in drug‑eluting biologic technologies, delivering both clinical and financial upside.